A New Series Of 1,3-Dimethylxanthine Based Adenosine A2a Receptor Antagonists As A Non-Dopaminergic Treatment Of Parkinson's Disease.

CONCLUSION: A new series of 7-substituted 8-m/p-chloropropoxyphenylxanthines having good affinity for A2A AR and potent antiparkinsonian activity has been developed. PMID: 32860362 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32860362?dopt=Abstract

Source: Current Drug Discovery Technologies - August 26, 2020 Category: Drugs & Pharmacology Authors: Rohilla S, Bansal R, Chauhan P, Kachler S, Klotz KN Tags: Curr Drug Discov Technol Source Type: research

More News: Drugs & Pharmacology | Parkinson's Disease | Study